Trenton, December 2, 2025 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey, released the following statement concerning the latest government-imposed price controls on life-saving medicines announced by the Centers for Medicare and Medicaid Services (CMS).
“As we’ve repeatedly emphasized, there are intelligent and effective ways to reduce health care costs with immediate benefits for patients, but government price-setting is not one of them. Not only do artificial price controls overlook the exceptionally costly and risky efforts involved in treating and curing diseases, but they also ignore other participants in the supply chain who contribute to rising costs, such as pharmacy benefit managers (PBMs), which are under investigation for their unfair practices that increase prices for patients.
Buteas continued, “This industry has cured hepatitis C, discovered the first life-altering treatment for sickle cell disease, developed vaccines against cervical cancer, launched the first-ever treatment to delay the onset of Alzheimer’s, extended the lives of cystic fibrosis patients by decades, and led the world out of the global COVID-19 pandemic. But there’s still more to do, and this latest round of Inflation Reduction Act price controls will stifle the innovation necessary to research and discover new treatments for patients. We will continue working with all stakeholders – federal and state policymakers and especially patient groups desperately awaiting the discovery of new treatments and cures – on policies that protect the patient community, promote medical innovation, and support jobs in New Jersey.”